Clinical Trial

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.
Protocol Amendment History 3 changes
notable Enrollment increased: 24 -> 36 participants 2026-07-29
notable Primary completion pushed: 2028-07-12 -> 2028-11-29 2026-07-29
minor Completion pushed: 2029-11-27 -> 2030-04-19 2026-07-29
Trial Details
NCT Number NCT07024563
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Enrollment 36 participants
Start Date 2025-06-14
Primary Completion 2028-11-29 (estimated)
Study Completion 2030-04-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-30